Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data Structure Therapeutics Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2023
FY2023
FY2024
FY2025
Research and development
36.2
70.1
109
225
General and administrative
16.4
32.7
49.4
61.6
Operating expenses
52.6
103
158
177
Operating income
-52.6
-103
-158
-177
Pre-tax income
-51.3
-89.4
-122
-141
Income tax
0.02
0.24
0.31
0.52
Net income
-51.3
-89.6
-123
-141
EBITDA
-52.3
-102
-157
-175
EPS, basic
-5.51
-0.81
-0.78
-0.80
EPS, diluted
-5.51
-0.81
-0.78
-0.80
Shares, basic (weighted)
9.58
110
158
178
Shares, diluted (weighted)
9.58
110
158
178
Balance sheet
FY2023
FY2023
FY2024
FY2025
Cash and equivalents
26.1
130
170
800
Short-term investments
64.8
338
714
647
Other current assets
2.25
6.29
7.69
24.1
Total current assets
93.1
474
891
1,570
Property, plant and equipment
1.03
3.23
3.48
6.65
Lease right-of-use assets
0.26
5.14
3.54
6.25
Other non-current assets
3.46
0.05
5.11
0.72
Total assets
97.8
482
903
1,584
Accounts payable
6.01
4.74
8.02
13.9
Accrued liabilities
3.54
4.33
7.29
12.4
Total current liabilities
13
24.7
36
63.3
Lease liabilities
4.01
2.16
3.61
Other non-current liabilities
0.3
0.3
0.65
Total liabilities
13
29.1
38.5
67.5
Paid-in capital
1.92
659
1,193
1,986
Retained earnings
-117
-207
-329
-470
Other comprehensive income
-0.11
0.52
0.91
1.05
Shareholders' equity
-115
453
865
1,516
Total equity
-115
453
865
1,516
Total liabilities and equity
97.8
482
903
1,584
Shares outstanding
10.5
139
172
213
Cash flow statement
FY2023
FY2023
FY2024
FY2025
Net income
-51.3
-89.6
-123
-141
Depreciation and amortization
0.28
0.3
0.99
1.33
Stock-based compensation
2.51
8.19
18.8
29
Change in payables
2.15
-0.86
3.31
4.77
Cash from operations
-46.1
-79.5
-117
-222
Capital expenditures
-0.16
-2.17
-1.29
-3.61
Purchases of investments
-123
-417
-703
-547
Cash from investing
-62.1
-268
-359
89.8
Stock issued
0.03
0.8
515
4.53
Cash from financing
29
452
515
763
Net change in cash
-79.2
104
39.7
630
Free cash flow
-46.3
-81.7
-118
-226
Income taxes paid
0.01
0.37
0.63
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $35.93 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-15.9%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-15.1%
Net income / average total assets.
Return on invested capital (ROIC)
-18.8%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
75.3%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
75.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
153.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
12.5%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
164.6%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
20.8x
Current assets / current liabilities.
Quick ratio
20.3x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
20.3x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$1.03
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.01
Cash from operations / diluted weighted shares.
Book value per share
$6.34
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
1.89x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.89x
Market cap / tangible book value, when positive.
FCF yield
-8.8%
Free cash flow / market cap.
Earnings yield
-8.4%
Net income / market cap (the inverse of P/E).
Was Structure Therapeutics Inc. profitable in fiscal 2025?
No. It reported a net loss of $141.2M.
How much free cash flow did Structure Therapeutics Inc. generate in fiscal 2025?
Cash from operations of $222.2M minus capital expenditures of $3.6M left free cash flow of -$225.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.